Navigation Links
NeoGenomics Schedules its Q3 2010 Earnings Release for October 28, 2010
Date:10/20/2010

NeoGenomics Schedules its Q3 2010 Earnings Release for October 28, 2010 -- FT. MYERS, Fla., Oct. 20 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
OTC, SmallCap, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Pharmaceuticals Click to view news release full screen  

NeoGenomics Schedules its Q3 2010 Earnings Release for October 28, 2010

 

FT. MYERS, Fla., Oct. 20 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (NASD OTC Bulletin Board: NGNM) announced today that it plans to release its third quarter 2010 financial results on Thursday, October 28, 2010.

The Company has scheduled a web-cast and conference call to discuss their Q3 2010 results on October 28, 2010, at 11:00 AM EDT.  Interested investors should dial (877) 407-8033 (domestic) and (201) 689-8033 (international) at least five minutes prior to the call.  A replay of the conference call will be available until 11:59 PM EDT on November 4, 2010 and can be accessed by dialing (877) 660-6853 (domestic) and (201) 612-7415 (international).  The playback account number is 359479 and the playback conference ID Number/PIN Number is 286.  The web-cast may be accessed under the Investor Relations section of our website at http://www.neogenomics.com or http://www.investorcalendar.com/IC/CEPage.asp?ID=162190.  An archive of the web-cast will be available until 11:59 PM EST on January 27, 2011.

About NeoGenomics, Inc.NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.  The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.  Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.For more news and information on NeoGenomics, please visit www.IRGnews.com/coi/NGNM where you can find a fact sheet on the company, investor presentations, and more.  Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at http://www.hawkassociates.com or from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/.

Forward-Looking StatementsExcept for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements.  These forward-looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.


'/>"/>

SOURCE NeoGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeoGenomics Schedules Its Q4 and Full Year 2009 Earnings Release for February 25, 2010
2. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
3. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
7. Schering-Plough Schedules Conference Call Webcast For 2009 Third Quarter Earnings
8. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
9. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
10. VirtualScopics Schedules Third Quarter 2009 Earnings Announcement
11. Innophos Holdings, Inc. Schedules Call to Discuss Fourth Quarter and Full Year 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
Breaking Medicine Technology:
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... a breakthrough topical cream that’s the first in a new class of photodynamic ... the overall appearance of skin, visibly reduce outward signs of aging, and minimize ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges ... for how his administration could impact the employee benefits industry. James Slotnick, AVP, ... most likely to make it through Congress. His discussion will focus on the ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... rely on contracted partners to help with process innovation in drug formulation and ... formulation experience along with state-of-the-art analytical equipment in support of their development and ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a ... its patient care management module. Using this new feature, sleep physicians can now ... initiated on continuous positive airway pressure (CPAP), oral, or other forms of sleep ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College is introducing ... advance their careers. Beginning in the fall of 2017, Emmanuel’s program will allow registered ... few as 16 months and for as little as $14,528. These changes will enable ...
Breaking Medicine News(10 mins):